Free tool
Cell therapy stocks
We cover 28 companies grouped under the Cell therapy theme. The median market value in the group is $377.80M. Across the group, the median move over the past trading day is −0.23%. 59% of the 27 with a 200-day average trade above it. Price change over the past year runs from −41.1% to +171.3% across the middle 80 percent of the group, with a median of +25.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
28 of 86 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| BLFS | BioLife Solutions, Inc. | $37.00 | +15.70% | +54.88% | +45.50% |
| VOR | Vor Biopharma Inc. | $23.67 | +18.35% | +103.35% | −40.82% |
| SANA | Sana Biotechnology, Inc. | $4.16 | +26.44% | −0.72% | +23.44% |
| IMMX | Immix Biopharma, Inc. | $14.07 | +66.71% | +159.12% | +617.86% |
| ALLO | Allogene Therapeutics, Inc. | $2.04 | +22.89% | +51.11% | +75.86% |
| PROK | ProKidney Corp. | $1.74 | +12.99% | −21.97% | −30.12% |
| AUTL | Autolus Therapeutics plc | $2.33 | +60.69% | +24.60% | +48.41% |
| ARTV | Artiva Biotherapeutics, Inc. | $11.77 | +11.78% | +178.25% | +259.94% |
| KYTX | Kyverna Therapeutics, Inc. | $8.61 | +14.95% | −1.82% | +133.33% |
| CABA | Cabaletta Bio, Inc. | $3.25 | +19.05% | +47.06% | +116.67% |
| 4592.T | SanBio Company Limited | 997.00 JPY | +10.78% | −39.10% | −57.08% |
| CAPR | Capricor Therapeutics, Inc. | $9.36 | +42.47% | −66.94% | +49.76% |
| 005690.KS | Pharmicell Co., Ltd. | 10,850.00 KRW | +20.82% | −24.76% | −0.03% |
| IPSC | Century Therapeutics, Inc. | $2.14 | +4.39% | +115.08% | +315.53% |
| LYEL | Lyell Immunopharma, Inc. | $15.49 | +19.25% | −46.55% | +37.32% |
| ALCLS.PA | Cellectis S.A. | 2.94 EUR | +16.59% | −30.30% | +27.74% |
| 219A.T | HEARTSEED INC | 2,435.00 JPY | +48.48% | +34.90% | −30.13% |
| CLLS | Cellectis S.A. | $3.42 | +20.42% | −28.75% | +28.09% |
| RNAC | Cartesian Therapeutics, Inc. | $10.19 | +33.20% | +50.74% | −4.09% |
| FATE | Fate Therapeutics, Inc. Common Stock | $2.57 | +10.78% | +159.60% | +129.46% |
| 4894.T | Cuorips Inc. | 5,720.00 JPY | +35.06% | −8.04% | −15.38% |
| LCTX | Lineage Cell Therapeutics, Inc. | $1.12 | +4.67% | −31.71% | −8.20% |
| 4593.T | Healios K.K. | 286.00 JPY | +34.91% | +1.78% | −41.63% |
| 7774.T | Japan Tissue Engineering Co., Ltd. | 847.00 JPY | +40.00% | +44.79% | +75.00% |
| NKTX | Nkarta, Inc. | $2.63 | +18.47% | +40.64% | +17.41% |
| 504A.T | Innovacell Inc. | 570.00 JPY | +3.07% | −45.71% | −45.71% |
| OCC.AX | Orthocell Limited | 0.76 AUD | +6.29% | −32.14% | −36.67% |
| MXCT | MaxCyte, Inc. | $1.31 | +24.76% | −15.48% | −6.43% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.